Population-based survival rates after curative surgical and non-surgical treatment of stage III NSCLC since 2017
Menée à partir des données 2017-2021 du registre néerlandais des cancers portant sur 1 293 patients atteints d'un cancer du poumon non à petites cellules de stade III, cette étude compare l'efficacité, du point de vue du taux de mortalité postopératoire à 90 jours et de la survie globale à 3 ans, de trois stratégies thérapeutiques néoadjuvantes à visée curative (chimioradiothérapie avec durvalumab en consolidation, chimiothérapie néoadjuvante et chirurgie, chimioradiothérapie et chirurgie)
Objectives: In stage III non-small cell lung cancer (NSCLC), curative treatment approaches used to include neoadjuvant therapy followed by surgery, and definitive chemoradiotherapy followed by consolidation durvalumab (CRT-ICI). Surgical strategies included either neoadjuvant chemotherapy (CTx-surg) or chemoradiotherapy (CRT-surg). We studied the outcomes of these three radical intent strategies in the Netherlands Cancer Registry (NCR) for patients diagnosed from 2017 to 2021. Materials and Methods: Patients with clinical stage III NSCLC (TNM edition 8) were identified in the NCR after excluding patients with known driver mutations, ECOG performance status >=2, N3-disease and those undergoing sequential chemoradiotherapy or single modality/palliative treatments. Overall survival (OS) was calculated from date of surgery or start of durvalumab. Results: Treatments delivered were CRT-ICI (n = 1016 patients), CRT-surg (n = 166) and CTx-surg (n = 111). The surgical series comprised 224 lobectomies, 21 bilobectomies and 32 pneumonectomies, with a 90-day postoperative mortality rate of 3.3 %. Use of CRT-surg decreased steeply after 2018, when durvalumab became fully reimbursed, and use of CRT-ICI increased. Three-year OS was better following CRT-surg (78.7 %) compared to CTx-surg (66.7 %) or CRT-ICI (63.2 %). After controlling for age, ECOG performance status and histology, the hazard ratios for CRT-surg and CTx-surg were 0.66 (95 % CI 0.47–0.91) and 0.82 (95 % CI 0.58–1.17), respectively, compared to CRT-ICI. Conclusion: Population survivals after curative strategies for clinical stage III NSCLC in The Netherlands exceed those reported historically for both surgical and non-surgical approaches. Use of surgery decreased from 2018 following the formal reimbursement of durvalumab. While variations in case-mix hamper comparison between curative treatment strategies, there is a clear need for randomized studies in subgroups with potentially resectable disease.
Lung Cancer 2024